ProfileGDS5678 / 1434580_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 78% 85% 73% 76% 75% 71% 71% 75% 75% 78% 74% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0720676
GSM967853U87-EV human glioblastoma xenograft - Control 24.9291975
GSM967854U87-EV human glioblastoma xenograft - Control 35.3422378
GSM967855U87-EV human glioblastoma xenograft - Control 46.5666785
GSM967856U87-EV human glioblastoma xenograft - Control 54.6574373
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.981976
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.8993775
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.480471
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.517871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.9858475
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9801475
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4799178
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8742774
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2100277